Azarga®

Write your review

Azarga®

• Quality

Title for your review^* Your review^* Your name^*

^* Required fields

Send

Locally. Shake the bottle before use.

1 drop in the conjunctival sac of the eye 2 times / day.

After using the drug to reduce the risk of systemic side effects, it is recommended that a finger lightly press onto the projection area of ​​the lacrimal sacs at the inner corner of the eye for 1-2 minutes after the drug is installed - this reduces the systemic absorption of the drug.

If the dose was missed, treatment should be continued with the next dose on a schedule. The dose should not exceed 1 drop in the conjunctival sac of the eye 2 times / day.

In case of replacement of any antiglaucoma drug with the drug Azarga, you should start using Azarga the day after the previous drug is canceled.

Adverse reactions

Local reactions: 1-10% of cases - blurred vision, eye pain, eye irritation, foreign body sensation; 0.1-1% of cases - corneal erosion, punctate keratitis, dry eye syndrome, eye discharge, itching in the eye, blepharitis, allergic conjunctivitis, effusion in the anterior chamber of the eye, conjunctival hyperemia, formation of crusts at the edges of the eyelids, asthenopia, feeling of discomfort in the eyes , itching, eyelid erythema, allergic blepharitis.

Systemic side effects: 1-10% of cases - dysgeusia; 0.1-1% of cases - insomnia, lower blood pressure, chronic obstructive pulmonary disease, pain in the oropharynx, rhinorrhea, cough, dysplasia, lichen planus.

Brinzolamide

Local reactions: keratitis, keratopathy, increased excavation of the optic nerve head, defect of the corneal epithelium, increased intraocular pressure, deposits on the cornea, formation of cornea defects, corneal edema, conjunctivitis, inflammation of the meibomian glands, diplopia, photophobia, photopsia, reduction of visual acuity, vision, reduction of visual acuity dry keratoconjunctivitis, eye hypesthesia, sclera pigmentation, subconjunctival cyst, increased tearing, blurred vision, eye swelling, allergic reactions of the eye, mydriasis, eyelid edema.

Systemic side effects: apathy, depression, decreased libido, nightmares, nervousness, drowsiness, motor dysfunction, amnesia, memory impairment, disturbances of the central nervous system.

Treatment: Immediately flush eyes with water. Symptomatic and supportive therapy. Electrolyte levels and blood pH should be monitored. Hemodialysis is ineffective.

With care: patients with hyperthyroidism, Prinzmetal angina, impaired peripheral and central blood circulation and arterial hypotension.

Contraindications

The experience of using Azarga for treating patients with pseudoexfoliative glaucoma, pigmentary glaucoma is limited: in these cases, the drug should be used with caution and constantly monitor intraocular pressure.

Anaphylactic reactions. Patients with atopy or severe anaphylactic reactions to various allergens in history, receiving beta-blockers, may be resistant to the usual doses of adrenaline in the treatment of anaphylactic reactions.

System effects Brinzolamide and timolol may undergo systemic absorption. When used locally, timolol can cause the same side effects of the cardiovascular and respiratory systems as systemic beta-blockers. The patient’s condition should be monitored before and during timolol therapy. Cases of severe respiratory and cardiovascular disorders are described, including death from bronchospasm in patients with bronchial asthma and death from heart failure with the use of timolol.

Beta-blockers should be used with caution in patients with a tendency to hypoglycemia or diabetes (especially with labile diabetes), since these drugs can mask the symptoms of acute hypoglycemia.

Before a planned operation, beta-blockers should be gradually (not simultaneously) canceled 48 hours before general anesthesia, sinceduring general anesthesia, they can reduce the sensitivity of the myocardium to the sympathetic stimulation required by the day of the heart.

Azarga contains brinzolamide, which is a sulfonamide. Since when applied topically, systemic absorption of the drug occurs, and side reactions characteristic of sulfonamides may occur. The development of acid-base imbalance in the use of oral forms of carbonic anhydrase inhibitors is described.

Drug interactions

Research on the interaction with other drugs was not conducted. Concurrent use with oral carbonic anhydrase inhibitors is not recommended, since There is a possibility of increased systemic adverse reactions.

Cytochrome P450 isoenzymes are responsible for the metabolism of brinzolamide: CYP3A4 (mainly), CYP2A6, CYP2B6, CYP2C8 and CYP2C9. It is necessary to prescribe with caution drugs inhibiting CYP3A4 isoenzyme, such as ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin, due to possible inhibition of the metabolism of brinzolamide. Care should be taken when co-prescribing inhibitors of the isoenzyme CYP3A4. However, accumulation of brinzolamide is unlikely, since it is excreted by the kidneys. Brinzolamide is not an inhibitor of cytochrome P450 isoenzymes.

There is a possibility of enhancing the hypotensive effect and / or the development of severe bradycardia with simultaneous use of timolol with calcium channel blockers for oral administration, guanethidine, beta-blockers, antiarrhythmic drugs, cardiac glycosides and parasympathomimetics.

The development of hypertension after abrupt withdrawal of clonidine may be enhanced while taking beta-blockers.

Strengthening the systemic action of beta-blockers (reducing heart rate) can develop with the simultaneous use of inhibitors of CYP2D6 (quinidine, cimetidine) and timolol.

Beta-blockers may enhance the hypoglycemic effect of antidiabetic agents. Beta-blockers may mask the symptoms of hypoglycemia.

In case of use with other local ophthalmologic preparations, the interval between their use should be at least 15 minutes.

Pregnancy and Lactation

Special instructions